The FDA approval of pritelivir offers an oral treatment for refractory HSV lesions in immunocompromised adults, with drug interactions creating an important role for pharmacists.
|Articles|May 24, 2022
Daily Medication Pearl: Prezista (Darunavir)
Author(s)Saro Arakelians, PharmD
Prezista is an protease inhibitor indicated for the treatment of HIV-1 infection in patients aged 3 years and older.
Advertisement
Medication Pearl of the Day: Prezista (Darunavir)
Indication: Prezista is an protease inhibitor indicated for the treatment of HIV-1 infection in patients aged 3 years and older.
Insights:
- Dosing: Treatment-experienced and -naïve adult patients with no darunavir resistance-associated substitutions: 800 mg (2 400-mg tablets) taken with ritonavir 100 mg once daily and with food
- Dosage forms: 100 mg/mL oral suspension-75 mg tablets, 150-mg tablets, 400-mg tablets, and 600-mg tablets
- Adverse events: The most common clinical adverse drug reactions to Prezista/ritonavir (an incidence equal to greater than 5%) of at least moderate intensity (equal to or greater than grade 2) were abdominal pain, headaches, diarrhea, nausea, rash, and vomiting.
- Mechanism of action: Darunavir is an HIV-1 antiviral drug.
- Manufacturer: Janssen Pharmaceuticals
Source:
Advertisement
Related to this article
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague, and which antibiotics the CDC recommends.
Pharmacists can address patient fears about fentanyl by distinguishing illicit from prescribed opioids and promoting safe, empathetic, evidence-based opioid use.
Victoria P. Werth, MD, discusses how litifilimab’s 52-week AMETHYST findings inform treatment expectations and timely reassessment of persistent cutaneous lupus symptoms.
In an interview with Pharmacy Times, Victoria P. Werth, MD, professor of dermatology at the University of Pennsylvania and chief of dermatology at the Philadelphia VA Medical Center, discusses why meaningful improvement extends beyond skin clearance and how response timing affects patients with difficult-to-control disease.
As psychedelic therapies advance through clinical development, pharmacists should prepare for potential roles in their safe, evidence-based integration into patient care.
In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, discusses what the hospitalization findings mean for patients and why they should be viewed as supportive evidence
Emergency and ICU pharmacists would be most likely to see pneumonic plague. An expert reviews first-line agents, alternatives, and postexposure prophylaxis.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Preparing Pharmacists for Psychedelic Medicine
2
Pneumonic Plague: What Pharmacists Need to Know About Treatment
3
Beyond Skin Clearance: What Litifilimab Could Mean for Cutaneous Lupus Care
4
National Pharmacy Technician Day: Celebrating the Backbone of Pharmacy
5